

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

4

## **Complete if Known**

Application Number	10/535,500
Filing Date	May 18, 2005
First Named Inventor	Anne Mette Buhl HERTZ, et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	55320.001041

## **OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/AMG/	7.	Damie et al., "B-Cell Chronic Lymphocytic Leukemia Cells Express a Surface Membrane Phenotype of Activated, Antigen-Experienced B Lymphocytes", Blood, Vol. 99, No. 11, pg. 4087-4090, 2002.	
	8.	Hamblin, "Chronic Lymphocytic Leukaemia: One Disease of Two?", Ann Hematol, Vol. 81, pg. 299-303, 2002.	
	9.	Kröber, et al., "V <sub>H</sub> Mutation Status, CD38 Expression Level, Genomic Aberrations, and Survival in Chronic Lymphocytic Leukemia", Blood, Vol. 100, No. 4, pg. 1410-1416, 2002.	
	10.	Lin et al., "Relationship between p53 Dysfunction, CD38 Expression, and IgV <sub>H</sub> Mutation in Chronic Lymphocytic Leukemia", Blood, Vol. 100, No. 4, pg. 1404-1409, 2002.	
	11.	Jensen et al., "Rapid Tumor Lysis in a Patient with B-Cell Chronic Lymphocytic Leukemia and Lymphocytosis Treated with an Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab)", Ann Hematol, Vol. 77, pg. 89-91, 1998.	
	12.	Muzny et al., "Homo sapiens", 12 BAC RP11-693J15, Database EMBL, accession number AC063949, 2000.	
	13.	Andrews et al., "Reconstruction of a Functional Human Type II IL-4/IL-13 Receptor in Mouse B Cells: Demonstration of Species Specificity" J Immunol, Vol. 166, No. 3, pg. 1716-1722, 2001.	
	14.	Bouteiller et al., "Isolation of an IL-13-dependent Subclone of the B9 Cell Line Useful for the Estimation of Human IL-13 Bioactivity", Journal of Immunological Methods, Vol. 181, pg.29-36, 1995.	
	15.	Chaouchi et al., "Interleukin-13 Inhibits Interleukin-2-Induced Proliferation and Protects Chronic Lymphocytic Leukemia B Cells from In Vitro Apoptosis", Blood, Vol.87, No.3, pg.1022-1029, 1996.	
	16.	Damie et al., "Ig V Gene Mutation Status and CD38 Expression as Novel Prognostic Indicators in Chronic Lymphocytic Leukemia", Blood, Vol.94, No. 6, pg. 1840-1847, 1999.	
/AMG/	17.	Dancescu et al., "Interleukin 4 Protects Chronic Lymphocytic Leukemic B Cells from Death by Apoptosis and Upregulates Bcl-2 Expression" J. Exp. Med., Vol. 176, pg. 1319-1326, 1992.	

Examiner  
Signature

/Anne Gussow/

Date  
Considered

10/29/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

## **Complete if Known**

Application Number	10/535,500
Filing Date	May 18, 2005
First Named Inventor	Anne Mette Buhl HERTZ, et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	55320.001041

Sheet 3 of 4

## **OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/AMG/	18.	Dohner et al., "Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia", The New England Journal of Medicine, Vol. 343, No. 26, pg. 1910-1916, 2000.	
	19.	Fluckiger et al., "IL-13 has only a subset of IL-4-like Activities on B Chronic Lymphocytic Leukaemia Cells", Immunology, Vol. 83, No. 3, pg. 397-403, 1994.	
	20.	Hamblin, et al., "Unmutated Ig V <sub>H</sub> Genes are Associated with a More Aggressive Form of Chronic Lymphocytic Leukemia", Blood, Vol. 94, No. 6, pg. 1848-1854, 1999.	
	21.	Jorgensen et al., Differential Display Competitive Polymerase Chain Reaction: An Optimal Tool for Assaying Gene Expression", Electrophoresis, Vol. 20, pg. 230-240, 1999.	
	22.	Kim et al., "The Emerging Fields of Suicide Gene Therapy and Virotherapy", Trends in Molecular Medicine, Vol. 8, No. 4, pg. S68-S73, 2002.	
	23.	Kröber et al., "V <sub>H</sub> Mutation Status, CD38 Expression Level, Genomic Aberrations, and Survival in Chronic Lymphocytic Leukemia", Blood, Vol. 100, No. 4, pg.1410-1416, 2002.	
	24.	Kyte et al., "A Simple Method for Displaying the Hydropathic Character of a Protein", Journal of Molecular Biology, Vol. 157, pg. 105-132, 1982.	
	25.	Liang et al., "Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction", Science, Vol. 257, pg. 967-971, 1992.	
	26.	Lundin et al., "Interleukin 4 Therapy for Patients with Chronic Lymphocytic Leukaemia: a phase I/II Study", British Journal of Haematology, Vol. 112, pg. 155-160, 2001.	
↓	27.	Luo et al., Antiproliferative Effect of Interleukin-4 in B Chronic Lymphocytic Leukemia", Journal of Immunotherapy, Vol. 10, pg. 418-425, 1991.	
/AMG/	28.	Merrifield, "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide", J. Am. Chem. Soc., Vol. 85, pg. 2149-2154, 1963.	

Examiner Signature	/Anne Gussow/	Date Considered	10/29/2007
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 4

**Complete if Known**

Application Number	10/535,500
Filing Date	May 18, 2005
First Named Inventor	Anne Mette Buhl HERTZ, et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	55320.001041

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/AMG/	29.	Panayiotidis et al., "Interleukin-4 Inhibits Apoptotic Cell Death and Loss of the bcl-2 Protein in B-Chronic Lymphocytic Leukaemia Cells <i>in vitro</i> ", British Journal of Haematology, Vol. 85, pg. 439-445, 1993.	
	30.	Petersen et al., "Optimisation of the CT.h4S Bioassay for Detection of Human Interleukin-4 Secreted by Mononuclear Cells Stimulated by Phytohaemagglutinin or by Human Leukocyte Antigen Mismatched Mixed Lymphocyte Culture", Immunology Letters, Vol. 84, pg. 29-39, 2002.	
	31.	Yazawa et al., "Current Progress in Suicide Gene Therapy for Cancer", World J. Surg., Vol. 26, No. 7, pg. 783-789, 2002.	
	32.	Oscier et al., Multivariate Analysis of Prognostic Factors in CLL: Clinical Stage, <i>IGH</i> gene mutational status, and Loss or Mutation of the <i>p53</i> gene are Independent Prognostic Factors", Blood, Vol. 100, No. 4, pg. 1177-1184, 2002.	
	33.	Standard Search Report in DK2002 01792, dated July 22, 2003.	
/AMG/	34.	International Search Report in PCT/DK03/00794, dated Augst 16, 2004.	

Examiner  
Signature

/Anne Gussow/

Date  
Considered

10/29/2007

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		<b>Application Number</b>	<b>10/535,500</b>
		<b>Filing Date</b>	<b>May 18, 2005</b>
		<b>First Named Inventor</b>	<b>Anne Mette Buhl HERTZ, et al</b>
		<b>Art Unit</b>	<b>Unassigned</b>
		<b>Examiner Name</b>	<b>Unassigned</b>
<b>Sheet</b>	<b>1 of 1</b>	<b>Attorney Docket Number</b>	<b>55320.001041</b>

**OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
/AMG/	1.	Written Opinion issued in International Application No. PCT/DK03/00794, dated October 27, 2004.	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>

<b>EXAMINER SIGNATURE</b> /Anne Gussow/	<b>DATE CONSIDERED</b> 10/29/2007
---	-----------------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.